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​The widespread use of Next Generation Sequencing (NGS) has allowed multi-gene panel             
testing to become common practice in clinical cancer genetic testing over the past six years. Over                
this time, guidelines have been established and modified, but there is no consensus on how panel                
testing should be utilized in cancer genetic counseling. There is also limited research into how               
cancer genetic testing is ordered among different providers. In our study, 1,402 cancer genetic              
tests were ordered by a variety of provider types from a large academic institution consisting of                
16 private and public hospitals as well as a laboratory serving the Long Island and New York                 
City metropolitan area. Data was collected between 01/01/2018 and 09/30/2019 and analyzed to             
identify discrepancies in the ordering practices among different provider types. Out of the 1,402              
cancer genetic tests ordered, 505 were general multi-gene panels, 330 of which were ordered by               
genetic counselors and geneticists, and the other 175 were ordered by a variety of non-genetics               
providers. Based on our analysis, there is a statistically significant difference (P-value < 0.0001)              
in test ordering practices among genetics and non-genetics providers. Our study serves as a              
foundation for future research into these discrepancies, as well as for research into how to rectify                
these differences in test ordering practice. 
Key Words 
Cancer genetic counseling, genetic testing, multi-gene panel testing, hereditary cancer genetics,           
genetic test ordering practices 
Introduction 
Hereditary cancer genetic testing began before the discovery of the ​BRCA1 ​and ​BRCA2             
genes; however, once these genes were uncovered, they became the primary target of breast              
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cancer genetic testing for their role in contributing to Hereditary Breast and Ovarian Cancer              
(HBOC) (Shah & Nathanson, 2017). The ​BRCA1 ​and BRCA2 genes were identified and patented              
by Myriad Genetics in 1994 and 1996, respectively. Myriad offered sequencing on the ​BRCA1              
and ​BRCA2 genes for a limited number of patients with a greater than 30% predicted risk of                 
having a mutation in either gene. In 2006, Myriad integrated deletion and duplication testing for               
patients who were negative for Sanger sequencing but still at a high risk for having a ​BRCA1/2                 
mutation (King & Mahon, 2017). In 2013, the Supreme Court of the United States ruled that                
genes cannot be patented, ending Myriad’s monopoly on ​BRCA1/2 testing (​Association for            
Molecular Pathology et al. v. Myriad Genetics, Inc., et al.​, ​2013). Multiple genetic testing              
laboratories began offering testing for ​BRCA1/2 ​along with several other genes implicated in             
hereditary cancer syndromes (King & Mahon, 2017), which greatly increased the number and             
diversity of tests offered. The rise of Next Generation Sequencing (NGS) dramatically reduced             
the cost of analyzing genes, and its use skyrocketed for clinical purposes in multi-gene panel               
testing (Willoughby, Andreassen, & Toland, 2019). NGS technologies allow for massively           
parallel sequencing (MPS) alongside deletion/duplication analysis of multiple genes         
simultaneously. This has allowed the scope of cancer genetic testing to rapidly expand with              
clinical cancer research to include analysis of several other genes associated with hereditary             
breast and ovarian cancers (King & Mahon, 2017; Willoughby, Andreassen, & Toland, 2019). 
Together ​BRCA1 and ​BRCA2 ​are responsible for up to half of heritable breast cancers              
(Tung et al., 2015); however, variants in ​BRCA1/2 do not explain all cases of HBOC. A                
significant proportion of cases may be due to a pathogenic or likely pathogenic variant in a breast                 
cancer-associated gene that is not ​BRCA1 ​or ​BRCA2 ​(Beitsch et al., 2018; Tung et al., 2015).                
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Multi-gene panel testing is defined, for the purposes of this study, as genetic testing which               
analyzes genes for multiple hereditary cancer predisposition syndromes at once, in contrast to             
syndrome-specific testing which may look at only one or a few genes distinct to a particular                
hereditary cancer syndrome. Panel testing comes with its own challenges which can arise in test               
interpretation: the discovery (and classification) of a variant of uncertain significance (VUS),            
testing low-risk populations, and understanding and conveying the impact of rarer variants on             
risk assessment (Hiraki et al., 2014; Shah & Nathanson, 2017; Stanislaw et al., 2016; and Tung                
et al., 2015). 
Guidelines have been created by several different professional organizations to help           
providers identify appropriate candidates for cancer genetic testing. The National Society of           
Genetic Counselors (NSGC), the National Comprehensive Cancer Network (NCCN), the          
American College of Obstetricians and Gynecologists (ACOG), and the United States Preventive            
Services Task Force (USPSTF) have all published such position statements and guidelines.             
When it comes to recommendations regarding multi-gene panel testing, however, these           
organizations do not provide consistency in how they describe the utility of multi-gene panels              
and for which candidates they may be the most useful. This lack of consistency may provide a                 
potential source of discrepancy in how different providers select tests to order for their patients.               
Additional sources of discrepancies that can affect test ordering practices include differences in             
provider educational experiences in regard to genetics knowledge, ambiguous test results like            
variants of uncertain significance (VUS), and mutations identified in genes without clear            
management guidelines (Baars, Henneman, & ten Kate, 2005; Cragun et al., 2014b; Cox et al.,               
2012; Klitzman et al., 2012; King & Mahon, 2017; Miller et al., 2014; Richter et al., 2019).  
4 
Some recent recommendations are encouraging population-based cancer genetic testing         
for all patients with breast cancer (ASBrS, 2019; Beitsch et al., 2018; Helwick, 2015), yet               
significant barriers regarding population-based testing remain. These barriers include the          
varying educational and practice backgrounds of ordering providers, issues such as interpreting            
and disclosing VUS results, not having enough genetic counselors to support such a testing              
demand, and figuring out how to parse out cancer risks between families with different cancer               
histories (Willoughby, Andreassen, & Toland, 2019). 
After the Myriad patents ended in 2013, cancer genetic testing diversified along with the              
evolving technology, and guidelines were established to identify candidates for genetic testing.             
While more recent recommendations call for a shift towards population-based genetic testing,            
barriers remain to its implementation. Of these barriers, discrepancies in test ordering practices             
between different providers serves as an important consideration as little research has been done              
to investigate how ordering practices have changed over the past six years. The purpose of this                
study is to help bridge that gap by quantifying current trends in ordering practices of cancer                
genetic tests among different types of providers. 
Materials & Methods 
The data analyzed in this study consisted of cancer genetic tests ordered by several                
provider types. Data was sampled from an internal database shared by a large academic              
institution consisting of 16 private and public hospitals as well as a laboratory serving the Long                
Island and New York City metropolitan area. Collected data spanned from 01/01/2018 to             
09/30/2019. The parameters for sampling data included the type of cancer genetic tests ordered,              
the dates the tests were accessioned and verified, and the ordering clinician. Patient identifiers              
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and demographics were not collected. Duplicate entries and cancelled tests were excluded from             
analysis. 
The types of genetic tests ordered were grouped into four categories. The breast-specific             
category included ​BRCA1/2 ​gene sequencing and deletion/duplication analysis, site-specific         
analysis of the three Ashkenazi Jewish founder mutations (c.68_69delAG, c.5266dupC,          
c.5946delT), and small multi-gene panels containing 9-17 genes related to increased risk of             
hereditary breast cancer. The breast/GYN category included multi-gene panels containing 19-25           
genes related to increased risk of breast and gynecological cancers, which shares genes in              
common with panels for increased risk of gastrointestinal cancers. The Lynch/CRC category            
included multi-gene panels containing 5-20 genes associated with increased risk of colorectal            
cancers. The general multi-gene panel category included the largest multi-gene panels containing            
37-83 genes associated with increased risk of common hereditary cancers. The number of genes              
and the specific genes tested varied based on the genetic testing laboratory’s individual panel and               
were not included in the analysis.  
Ordering clinicians were identified based on their area of specialty as classified by their              
national provider identification (NPI) number. Clinicians were grouped into six categories:           
genetic counselors (GC) and geneticists (GC/Genetics), obstetricians and gynecologists         
(OBGYN), hematologists and oncologists (HemOnc), gastroenterologists (GI), surgeons        
(Surgery), and all other provider types sampled (Other). Other providers included internists,            
pathologists, nurse practitioners, physician assistants, midwives, and specialties otherwise         
unspecified. 
6 
The data were initially separated by year (2018 vs. 2019) and grouped based on test               
category. Three paired samples t-tests were run using Microsoft Excel for non-genetics, genetics,             
and all providers to identify potential biases in ordering practices between 2018 and 2019. One               
genetics provider’s data was excluded from these analyses because dates were not included to              
distinguish in which year the tests were ordered. This data was included in the remaining               
analysis, and the 2018 and 2019 data were aggregated together. A chi-square analysis was run               
using Microsoft Excel to identify if a relationship was present between provider type and the               
type of genetic test ordered in the aggregated data set. 
Results 
A total of 1,402 cancer genetic tests were ordered by all provider types between              
01/01/2018 and 09/30/2019. 640 tests (45.6%) fell into the breast-specific category, 164 tests             
(11.7%) were breast/GYN, 93 tests (6.6%) were Lynch/CRC, and 505 (36%) were general             
multi-gene panels (Appendix A: Figures (Figure 1)). 
When separating the tests by the year in which they were ordered, 52 tests were excluded                
from analysis due to missing accession dates. The total number of each test type ordered by year                 
is presented in Figure 2 (Appendix A: Figures). The tests were grouped by test type and a paired                  
samples t-test was run for non-genetics, genetics, and all providers to determine if test ordering               
practices differed between 2018 and 2019. For non-genetics, genetics, and all providers            
combined, the P-values were 0.34, 0.54, and 0.45, respectively, suggesting differences between            
test types ordered in 2018 and 2019 were not statistically significant (Appendix B: Tables (Table               
1)). Based on these results, the 52 excluded tests were reincorporated into the data set for further                 
analysis.  
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The test types ordered were separated into their constituent categories (breast-specific,           
breast/GYN, Lynch/CRC, general multi-gene panels) and stratified based on provider type           
(GC/Genetics, OBGYN, HemOnc, GI, Surgery, Other, All). Of the 640 breast-specific tests            
ordered, 110 were ordered by genetic counselors and geneticists, 78 were ordered by             
obstetricians and gynecologists, 70 were ordered by hematologists and oncologists, 2 were            
ordered by gastroenterologists, 60 were ordered by surgeons, and 320 were ordered by other              
provider types, predominantly internists (Appendix A: Figures (Figure 3)). Of the 164            
breast/GYN tests ordered, 118 were ordered by genetic counselors and geneticists, 9 were             
ordered by obstetricians and gynecologists, 4 were ordered by hematologists and oncologists, 1             
was ordered by gastroenterologists, 18 were ordered by surgeons, and 14 were ordered by other               
providers (Appendix A: Figures (Figure 4)). Of the 93 Lynch/CRC tests ordered, 42 were              
ordered by genetic counselors and geneticists, 5 were ordered by obstetricians and gynecologists,             
1 was ordered by hematologists and oncologists, 24 were ordered by gastroenterologists, none             
were ordered by surgeons, and 21 were ordered by other providers (Appendix A: Figures (Figure               
5)). Of the 505 general multi-gene panels ordered, 330 were ordered by genetic counselors and               
geneticists, 92 were ordered by obstetricians and gynecologists, 14 were ordered by            
hematologists and oncologists, 6 were ordered by gastroenterologists, 5 were ordered by            
surgeons, and 58 were ordered by other providers (Appendix A: Figures (Figure 6)).  
A chi-square analysis was run to determine if there was a relationship between the types               
of tests ordered and the type of provider ordering them. The chi-square value from this analysis                
was 704.977, which exceeded the critical value of 24.996. The resulting P-value from the              
analysis was <0.0001, which is a statistically significant result (Appendix B: Tables (Table 2)).              
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The observed types of tests ordered differed from expected based on which provider was              
ordering the test. When visualizing the data, it appears that genetics providers, including genetic              
counselors, tend to order larger or broader panels, such as the breast/GYN panel and the general                
multi-gene panels, more frequently than other providers considered in this analysis. 
Discussion 
Our null hypothesis postulates that there is no statistically significant difference in cancer             
genetic test ordering practices between genetics providers and non-genetics providers. Based on            
the results of our chi-square analysis we reject the null hypothesis. Our P-value (<0.0001)              
indicates that there is a statistically significant relationship between the type of cancer genetic              
test selected and the type of provider ordering the test. The overall trend, as demonstrated in the                 
figures, is that genetics providers order larger multi-gene panels more frequently compared to             
other types of providers.  
This point is particularly salient when looking at breast-specific testing in comparison to             
other categories of cancer genetic tests. Roughly 83% (530/640) of breast-specific tests were             
ordered by OBGYNs, HemOncs, surgeons, and other providers (largely internists), whereas 17%            
(110/640) were ordered by genetics providers. Breast specific tests are comparatively narrower            
in the scope of analysis because they look at fewer genes that predispose individuals to               
developing breast cancer compared to multigene panels which include genes associated with            
other types of hereditary cancer.  
The breast/GYN tests, which include a larger number of genes and identify a broader              
spectrum of cancer risks (compared to the breast specific tests), were ordered predominantly by              
genetics providers. Approximately 72% (118/164) of these tests were ordered by genetics            
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providers, whereas 28% (46/164) of breast/GYN panels were ordered by non-genetics providers.            
Similarly, around 65% (330/505) of general multi-gene panels were ordered by genetics            
providers, and 35% (175/505) were ordered by non-genetics providers, more than half of which              
were OBGYNs.  
Approximately 45% (42/93) of the Lynch/CRC panels were ordered by genetics           
providers, 26% (24/93) were ordered by GIs, and 29% (27/93) were ordered by other providers.               
While the majority of genetic testing was ordered by non-genetics providers, GIs are more likely               
to encounter individuals with colorectal and other types of gastrointestinal cancers compared to             
other provider types. The delineation as to whether or not a colorectal or gastrointestinal cancer               
is due to a hereditary predisposition may also fall into the scope of practice more frequently for                 
genetics providers and GIs than for other provider types.  
There are several factors that may contribute to discrepancies in test ordering practices             
between different provider types, including provider educational background and understanding          
of genetics as well as inconsistencies between cancer genetic testing guidelines. Baars,            
Henneman, and ten Kate (2005) sampled general practitioners, gynecologists, and pediatricians           
to examine the differences in providers’ knowledge of genetic concepts and genetic testing.             
When providers have exposure to genetics in their training or provide genetic counseling to              
patients, they demonstrate having more knowledge about genetics and testing principles than            
providers with limited exposure (Baars, Henneman, & ten Kate, 2005). In a small sample of               
internists in the US, Klitzman et al. (2012) demonstrated that 73.7% of the providers surveyed               
rated their knowledge of genetics as very/somewhat poor, and 87.1% rated their knowledge of              
the guidelines for genetic testing as very/somewhat poor. 79% of respondents felt they needed              
10 
more training on when to order testing, 82% felt they needed more training on how to counsel                 
patients, and 77.3% felt they needed more training on how to interpret the results of genetic tests,                 
addressing the need for increased training in these areas (Klitzman et al., 2012). Within the same                
study, 44% of providers reported ordering genetic testing for their patients (Klitzman et al.,              
2012), which may include providers who are knowledgeable as well as those who may not feel                
as well-equipped to counsel patients. Cox et al. (2012) report that several providers, including              
primary care physicians, OBGYNs, surgeons, and oncologists, feel insecure about their           
knowledge of genetics. Of note, the most common reason a provider of any classification did not                
recommend or order genetic testing was a lack of familiarity (Cox, 2012). While these studies               
were able to comment on providers' perception of their knowledge of cancer genetics and genetic               
testing, it is important to note that both studies were published prior to the availability of large                 
multigene cancer panels.  
Our research did not address the demographics of the patients or the indications for              
genetic testing to determine adherence to published guidelines for genetic testing. In 2013, the              
NSGC released a practice guideline for risk assessment and genetic counseling for hereditary             
breast and ovarian cancer. NSGC recommends that providers who are considering ordering            
genetic testing should consult professional guidelines from organizations such as the National            
Comprehensive Cancer Network (NCCN) and the American College of Obstetricians and           
Gynecologists (ACOG). The NSGC 2017 position statement also supported the use of            
multi-gene panel testing with the caveat that it be done thoughtfully in context of the patient as                 
well as the parameters of the test’s clinical validity and utility, the limitations of the technology,                
and the ways in which variants are interpreted and reported. NSGC advises that knowledgeable              
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experts should order these tests because multi-gene panel testing may present with complications             
(NSGC, 2017).  
Recommendations from NCCN are regularly updated, and while we acknowledge there           
are newer guidelines available in 2020, our research analysis primarily relies on guidelines             
released in 2018 and 2019. At the time of data collection, the NCCN guidelines for               
Genetic/Familial High Risk Assessment: Breast and Ovarian ​were updated in 2019 (v.3.2019)            
while the ​Genetic/Familial High Risk Assessment: Colorectal ​guidelines were updated in 2018            
(v.1.2018). According to the NCCN (2019) genetic/familial high risk assessment for breast and             
ovarian cancer guidelines, it remains inappropriate to utilize multi-gene testing when a patient             
has a personal or family history indicative of a single hereditary cancer predisposition syndrome.              
Syndrome-specific testing is suggested as it tests for more than one gene that may be responsible                
for the suspected inherited cancer syndrome, albeit with a more limited scope of analysis. In the                
context of breast and ovarian cancers, NCCN (2019) suggests that multi-gene panel testing may              
be utilized when a patient tests negative for a suspected hereditary cancer predisposition             
syndrome and when the personal and/or family history remains suspicious of an inherited             
syndrome (NCCN, 2019). In following the NCCN (2019) breast and ovarian cancer guidelines,             
one or two tests may be ordered depending on the patient’s initial result and personal/family               
history of cancer. The NCCN guidelines for genetic/familial high risk assessment of colorectal             
cancer highlight scenarios where multi-gene panel testing should be considered: when personal            
and/or family history meets criteria for more than one hereditary cancer syndrome, when the              
patient has colon polyposis with uncertain histology, when the family history of cancer does not               
meet guidelines for testing but there is an appropriate panel based on risk, in patients with                
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limited or unknown family history and a concern for cancer, in cases of adenomatous polyposis,               
and as second-line testing when the results of prior testing is inconclusive (NCCN, 2018). The               
breast and ovarian cancer guidelines from NCCN (2019) do not provide similar examples for              
when multi-gene panel testing may be most useful, which can potentially contribute to             
discrepancies in test ordering practices due to inconsistency of information.  
Another point of consideration in ordering cancer genetic tests is that different            
commercial laboratories analyze different genes, so it is important for the ordering provider             
(regardless of specialty) to choose the laboratory and specific panel with care. Providers should              
be aware that clinical features of hereditary breast and ovarian cancer syndrome overlap with              
features of other hereditary cancer syndromes that are due to different underlying genes             
(Berliner, Fay, Cummings, & Burnett, 2013). Based on the results of our analysis, non-genetics              
providers may be either ordering syndrome-specific testing only or ordering up to two cancer              
genetic tests for their patients, whereas genetics providers may be more likely to order              
multi-gene panels from the outset as they cover multiple cancer predisposition syndromes            
simultaneously, which is a point indicated in the NCCN colorectal guidelines and not the breast               
and ovarian cancer guidelines.  
 The guidelines suggested by NCCN differ from those suggested by ACOG. ACOG’s            
committee opinions recommend that OBGYNs should perform hereditary cancer risk          
assessments for their patients (ACOG, 2015). They also suggest that providers offering genetic             
testing, including OBGYNs, should provide pre- and post-test counseling for patients that            
includes a discussion about the benefits and limitations of testing, the ability to opt-out of testing                
(which is not directly stated in the NCCN guidelines), and potential effects testing has on               
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insurance. While ACOG does not disclose or recommend which genetic tests to offer patients,              
they do suggest that OBGYNs should establish consistent testing strategies within their practice             
so patients receive consistent care (ACOG, 2017). Additionally, if OBGYNs feel unable to             
counsel patients effectively about genetics and genetic testing, they should refer patients to a              
genetics specialist (ACOG, 2017). ACOG practice guidelines for multi-gene panel testing in            
hereditary breast cancer closely mirror those discussed in NCCN guidelines for the same             
hereditary cancer syndromes, and NCCN guidelines are primarily referenced to review the utility             
of multi-gene panel testing (​Hereditary breast and ovarian cancer syndrome​, 2017). The ACOG             
practice bulletin on Lynch syndrome from 2015 was reaffirmed in 2019 recommending that             
testing begin with tumor testing and immunohistochemistry (IHC) or microsatellite instability           
testing (MSI). This practice bulletin, however, does not address panel testing of multiple genes              
involved in the mismatch repair pathway and instead focuses on tumor testing being the first               
method of testing (​Lynch Syndrome, ​2014). 
The conclusions made by Beitsch et al. (2018) regarding the yield of multi-gene panel              
testing to capture mutations in genes other than ​BRCA1/2 ​influenced The American Society of              
Breast Surgeons (ASBrS) to publish guidelines in 2019 that recommended genetic testing for all              
patients with breast cancer. In contrast, the USPSTF’s 2019 draft recommendations upheld that             
genetic testing should only be offered when a woman screens positive on a brief familial risk                
assessment tool that is validated to predict the risk of carrying a mutation in ​BRCA1/​2 (USPSTF,                
2019).  
The continual updates and modifications to guidelines and testing recommendations          
creates a lag time between the publication of updates and implementation in clinical practice.              
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Over the timeframe of data collection, modifications were made to testing practices established             
by NCCN, ACOG, USPSTF, and ASBrS. While other recommendations, such as the 2014             
recommendation by Dr. Mary-Claire King proposing that all women at age 30 (regardless of              
family history) should be tested for ​BRCA1/2 ​germline mutations to decrease incidences of             
hereditary breast and ovarian cancers (Helwick, 2015) have remained unchanged. When           
comparing the genetic tests ordered in 2018 and 2019 in our dataset, the differences between the                
types of testing ordered were not statistically significant for genetics, non-genetics, and all             
providers combined. This indicates that any changes in test ordering practice due to updated              
testing guidelines likely did not impact the number or type of testing ordered.  
While our primary scope of analysis centered on test ordering practices, we also             
evaluated the types of results generated from these tests and compared the percentages between              
genetics and non-genetics providers. Testing ordered by a genetics provider ended in a positive              
result in 15.71% of tests, compared to 7.25% in tests ordered by a non-genetics provider.               
Negative results occurred in 55% of tests ordered by genetics providers and 77.38% of tests               
ordered by non-genetics providers. VUS results occurred in 29.29% of tests ordered by genetics              
providers and 15.38% of tests ordered by non-genetics providers. Overall, the testing ordered by              
genetics providers produced a higher percentage of positive and VUS results (Appendix B:             
Tables (Table 3)). These differences could be reflective of genetics providers ordering larger             
panels compared to non-genetics providers. Zirkelbach et al. (2018) found that genetic            
counselors tend to order multi-gene panels more frequently than syndrome-specific or other            
limited-gene tests. The study produced no difference in the number of variant discrepancies             
(VUS classifications) discovered by providers ordering panel testing versus providers ordering           
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syndrome-specific testing, indicating that providers ordering syndrome-specific panels were not          
doing so to avoid results with discrepancies. Overall, the surveyed genetic counselors agreed that              
there was a lack of data sharing, lack of a central database, lack of educational resources, and                 
lack of communication between the laboratories. The genetic counselors also indicated that when             
discrepancies occur they tailor recommendations to include personal and family history for a             
personalized risk, making it clear that the care of patients goes beyond the results of a genetic                 
counseling panel (Zirkelbach et al., 2018). 
Limitations and Future Research Directions 
There were several limitations to this study. Notably, the data is inclusive of a single               
academic institution and may not be representative of all providers or provider types. It would be                
valuable to replicate this study using data from multiple institutions, including ones that may be               
more targeted in their approach to cancer genetic testing. In this particular study population,              
non-genetics providers ordered testing solely through two laboratories for the types of            
cancer-specific panels mentioned above whereas the genetics providers utilized additional          
genetic testing laboratories, and testing included syndrome-specific testing in addition to the            
cancer-specific panels. Syndrome-specific testing, which tests a single gene or a few genes             
related to a specific hereditary cancer predisposition syndrome, is the most straightforward form             
of genetic testing that carries a lower potential for a VUS result as well as a quicker turnaround                  
time that may have importance in the medical management of cancer (Hall et al. 2014).  
Lynch syndrome testing, while commonly tested for in the field of genetics, can be              
considered a syndrome-specific test since it looks at a limited set of genes specifically distinct to                
this syndrome. Although not included as part of our analysis, we recorded that 53              
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syndrome-specific tests were ordered by genetic counselors for hereditary cancer predisposition           
syndromes other than Lynch syndrome. Appropriate test codes were not available to investigate             
syndrome-specific testing patterns in other providers, so this may be an area for future              
investigation that can further delineate trends in cancer genetic testing practices among different             
providers. 
Clinical indications for genetic testing were not available and not included in this             
analysis. As a result, it is unclear which proportions of the patients tested were personally               
affected with cancer and potentially looking to make treatment decisions and which proportions             
were unaffected and looking to understand and manage future cancer risks. Patient demographics             
including age, gender, personal history of cancer, ethnicity, insurance coverage, and education            
level were not considered in our analysis. Review of the current literature shows patient              
demographics such as age, sex, education, and socioeconomic status all play a role in how               
patients perceive and are able to access healthcare as well as the type of genetic testing a patient                  
chooses to undergo (or to decline) (Olaya et al., 2009; Richter et al., 2013; Trivedi et al., 2019).                  
Patients can seek coverage for genetic testing through their health insurance company or pay for               
it out-of-pocket. Some insurance companies require a patient to have pre- and post-test             
counseling by a board certified genetic counselor to have their testing covered (King & Mahon,               
2017), but there is no guarantee that a patient’s insurance company will cover a genetic test.                
Some patients do not have insurance and may be unable to afford genetic testing out-of-pocket,               
but insurance status does not seem to significantly affect patients’ decisions to undergo testing              
(Olaya et al., 2009; Trivedi et al., 2019). On the other hand, those with a personal history of                  
breast cancer and a higher level of education were more likely to have genetic testing.               
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Individuals with VUS results and lower levels of education (i.e. high school) also tended to               
incorrectly recall their result as well as the associated risk (Richter et al., 2013).  
The specific genetic testing results were also not included in our analysis as our data only                
indicated positive, negative, or VUS results. Understanding the specific gene that was positive             
can give insight into the clinically actionable decisions inherent in that result. Testing can              
uncover a mutation in a lower penetrant gene that lacks specific management guidelines at this               
time. It can be argued that in the absence of available treatment or preventive measures, risk can                 
still be provided to that patient and that "personal utility" can be beneficial to the patient (Hiraki                 
et al., 2014). Alternatively, Shah and Nathanson (2017) argue the use of genetic testing and its                
importance is based solely on the follow-up interventions or screenings that will benefit the              
patients.  
Future research involves understanding more about these lower penetrance genes and           
how to incorporate them into an actionable composite risk score for the patient (Hiraki et al.,                
2014). Tung et al. (2016) acknowledge the controversy in the field due to lack of clinical utility                 
and uncertainty regarding the association of a mutation with the development of cancer (clinical              
validity). When mutations are found in genes with no current clinical guidelines for medical              
management, this can lead to inappropriate or unnecessary management for the patient. In an              
attempt to reduce this controversy, Tung et al. (2016) created a framework for clinicians to               
counsel and make clinical decisions, recognizing the importance of developing a framework as             
individuals will continue to be tested for moderate penetrance genes that do not have established               
guidelines for management while noting that the delineation of moderate and high penetrance             
18 
genes is arbitrary. There is complexity involved in understanding these moderate relative risks             
and how to apply these risks to medical management. 
Conclusion 
Our study aimed to identify discrepancies in cancer genetic test ordering practices among             
genetics providers, including genetic counselors and geneticists as well as non-genetics           
providers. Analysis of 1,402 cancer genetic tests ordered over the span of 01/01/2018 to              
09/30/2019 revealed that when the ordering provider was classified by provider type and ordered              
genetic tests were sorted by types of genes tested, there were discrepancies in test ordering               
practices. The 1,402 ordered tests were categorized into breast-specific panels, breast/GYN           
panels, Lynch/CRC panels, and general multi-gene panels including genes globally associated           
with common hereditary cancers. 505 of the 1,402 tests ordered (36%) were general multi-gene              
panels of which 330 were ordered by genetic counselors and geneticists. These discrepancies             
may be influenced by provider education and understanding of genetics, as well as patient              
demographics as suggested in the literature. While guidelines for test ordering have been             
proposed by different organizations, there are currently no guidelines to establish consistency            
among providers or across specialties. While our study was limited to a single institution, it was                
able to address that differences in test ordering practice are occurring among providers of that               
institution. Additional research will be necessary to see if ordering practice differs among             
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Appendix A: Figures 
 
Figure 1 






















































































Provider Type P-Value 
Non-Genetics Providers 0.34 
Genetics Providers 0.53 
All Providers 0.45 
P-values for three paired samples t-tests comparing test types ordered by non-genetics, genetics, 



































Chi-Square Value 704.977 
Critical Value 24.996 
P-Value 1.616E-140 



























Providers All Providers  
VUS 41 123 164 




2 8* 10 
Negative 77 619 696 
Total with 
results 140 800 940 
%VUS 29.29% 15.38% 17.45% 
%Positive 15.71% 7.25% 8.51% 
%Negative  55.00% 77.38% 74.04% 
 Genetic test results by provider type 
